This is a prospective, multicenter, cohort study. The high-risk, relapse and refractory AML patients were enrolled in this study. And the goal of this study is to study the effect of the parous female donor and young male donor on the outcomes of graft-versus-host disease (GVHD) prophylaxis underwent the combination of ATG and PTCy for haploidentical peripheral blood stem cell transplantation
ELN prognostic stratification high-risk group (see Appendix for criteria)
Non-remission (NR) AML: including primary refractory AML and NR patients after relapse.
Patients had to have a qualified haploidentical young male (≤30 years old) or female with a history of pregnancy;
Related donors had to be related donors matched 5/10-7/10 for HLA-A, -B, -C, -DQB1 and -DRB1 3. All the enrolled patients received a unified GVHD prevention regimen based on ATG and PTCy
Intermediate-low risk AML patients (ELN criteria);
Patients with extramedullary active lesions at the time of transplantation;
Haploidentical collateral donors;
Patients who refused allogeneic hematopoietic stem cell transplantation;